Business

Biotech, pharma, and money in science

Amgen
Business

Amgen still has no magic pill to solve its zero-growth problem

By Adam Feuerstein and Damian Garde

Alex Azar - Sworn In At The White House
Politics

Drug makers question idea to shake up how Medicare pays for certain drugs

By Erin Mershon and Ike Swetlitz

Biotech

Biogen’s rain-making rare-disease drug hits a sales slump

By Damian Garde

Biotech

Prothena scraps lead drug following mid-stage study failure

By Adam Feuerstein

Adam's Take

SEC extends probe into Northwest Biotherapeutics as financial struggles mount

By Adam Feuerstein

Interacting chromatin chains
Biotech

Startup unwinds the role of chromatin to target epigenetic changes in cancer

By Elizabeth Cooney

Pharmaceutical company Takeda
Business

Shire rejects Takeda’s $60 billion takeover bid

By Jonathan Saltzman — Boston Globe

Pharmalot

Supreme Court weighs whether to review a whistleblower case against Gilead

By Ed Silverman

Amazon direct care illo
Business

Can Amazon cut insurers out of primary care?

By Casey Ross

Dengvaxia vials
Health

WHO ruling could put fate of world’s first dengue vaccine on the line

By Helen Branswell

Dr. John Maraganore
Biotech

Trade secrets battle between Alnylam, Dicerna is just one of many

By Jonathan Saltzman — Boston Globe

Money
Business

How well do biotech and pharma pay? A breakdown by company

By Damian Garde

Akili screenshot
Business

A digital medicine company tries to adopt pharma’s patent game. Will it work?

By Rebecca Robbins

Business

Do you want to turn your bathroom into a medical lab?

By Scott Kirsner — Boston Globe

Elizabeth Holmes
Business

‘Therabros’ and ‘disappeared’ staffers: the 8 juiciest things we learned from John Carreyrou’s new Theranos book

By Rebecca Robbins

Diagnosis eye diabetes
Politics

FDA approves first AI software that can identify disease, no specialists needed

By Ike Swetlitz

Alexion Pharmaceuticals Inc
Business

Alexion buying Swedish biotech for $855 million to broaden rare disease pipeline

By Adam Feuerstein

Adam's Take

Biogen and the badly needed gene therapy acquisition that got away

By Adam Feuerstein

Cancer Chemotherapy
Pharmalot

Drug company payments appear to influence oncologists’ prescribing habits

By Ed Silverman

Amazon Boston
Business

As Mass. woos Amazon, governor acknowledges company will have an uphill battle in health care

By Damian Garde

Pharma

Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities

By Adam Feuerstein

STAT Plus panel
Biotech

Why are some of New York’s top investors bullish on biotech? The science is getting better

By Adam Feuerstein

Pill pack
Business

Feds broaden the definition of ‘pharmacy’ in a bid to level playing field for startups

By Casey Ross

Medicine
Pharma

Drug makers have to post policies for patients seeking experimental medicines. Not all do

By Erin Mershon

Data
In the Lab

Experts challenge digital health developers to show value in an often-hyped field

By Andrew Joseph

Adam's Take

Experimental drug might reduce fat in blood, but a NASH cure? Not so fast

By Adam Feuerstein

Business

Alkermes stumbles as FDA refuses to review depression drug

By Adam Feuerstein

Binge-drinking research
Exclusive

NIH rejected a study of alcohol advertising while pursuing industry funding for other research

By Sharon Begley

Pharma

Drug companies want Supreme Court to take eye-drop dispute

By Associated Press

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.